Cargando…

A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania

BACKGROUND: Effective mass drug administration (MDA) with anti-malarial drugs can clear the human infectious reservoir for malaria and thereby interrupt malaria transmission. The likelihood of success of MDA depends on the intensity and seasonality of malaria transmission, the efficacy of the interv...

Descripción completa

Detalles Bibliográficos
Autores principales: Shekalaghe, Seif A, Drakeley, Chris, van den Bosch, Sven, ter Braak, Roel, van den Bijllaardt, Wouter, Mwanziva, Charles, Semvua, Salimu, Masokoto, Alutu, Mosha, Frank, Teelen, Karina, Hermsen, Rob, Okell, Lucy, Gosling, Roly, Sauerwein, Robert, Bousema, Teun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169516/
https://www.ncbi.nlm.nih.gov/pubmed/21864343
http://dx.doi.org/10.1186/1475-2875-10-247
_version_ 1782211496808284160
author Shekalaghe, Seif A
Drakeley, Chris
van den Bosch, Sven
ter Braak, Roel
van den Bijllaardt, Wouter
Mwanziva, Charles
Semvua, Salimu
Masokoto, Alutu
Mosha, Frank
Teelen, Karina
Hermsen, Rob
Okell, Lucy
Gosling, Roly
Sauerwein, Robert
Bousema, Teun
author_facet Shekalaghe, Seif A
Drakeley, Chris
van den Bosch, Sven
ter Braak, Roel
van den Bijllaardt, Wouter
Mwanziva, Charles
Semvua, Salimu
Masokoto, Alutu
Mosha, Frank
Teelen, Karina
Hermsen, Rob
Okell, Lucy
Gosling, Roly
Sauerwein, Robert
Bousema, Teun
author_sort Shekalaghe, Seif A
collection PubMed
description BACKGROUND: Effective mass drug administration (MDA) with anti-malarial drugs can clear the human infectious reservoir for malaria and thereby interrupt malaria transmission. The likelihood of success of MDA depends on the intensity and seasonality of malaria transmission, the efficacy of the intervention in rapidly clearing all malaria parasite stages and the degree to which symptomatic and asymptomatic parasite carriers participate in the intervention. The impact of MDA with the gametocytocidal drug combination sulphadoxine-pyrimethamine (SP) plus artesunate (AS) plus primaquine (PQ, single dose 0.75 mg/kg) on malaria transmission was determined in an area of very low and seasonal malaria transmission in northern Tanzania. METHODS: In a cluster-randomized trial in four villages in Lower Moshi, Tanzania, eight clusters (1,110 individuals; cluster size 47- 209) were randomized to observed treatment with SP+AS+PQ and eight clusters (2,347 individuals, cluster size 55- 737) to treatment with placebo over three days. Intervention and control clusters were 1km apart; households that were located between clusters were treated as buffer zones where all individuals received SP+AS+PQ but were not selected for the evaluation. Passive case detection was done for the entire cohort and active case detection in 149 children aged 1-10 year from the intervention arm and 143 from the control arm. Four cross-sectional surveys assessed parasite carriage by microscopy and molecular methods during a five-month follow-up period. RESULTS: The coverage rate in the intervention arm was 93.0% (1,117/1,201). Parasite prevalence by molecular detection methods was 2.2-2.7% prior to the intervention and undetectable during follow-up in both the control and intervention clusters. None of the slides collected during cross-sectional surveys had microscopically detectable parasite densities. Three clinical malaria episodes occurred in the intervention (n = 1) and control clusters (n = 2). CONCLUSIONS: This study illustrates the possibility to achieve high coverage with a three-day intervention but also the difficulty in defining suitable outcome measures to evaluate interventions in areas of very low malaria transmission intensity. The decline in transmission intensity prior to the intervention made it impossible to assess the impact of MDA in the chosen study setting. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00509015
format Online
Article
Text
id pubmed-3169516
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31695162011-09-09 A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania Shekalaghe, Seif A Drakeley, Chris van den Bosch, Sven ter Braak, Roel van den Bijllaardt, Wouter Mwanziva, Charles Semvua, Salimu Masokoto, Alutu Mosha, Frank Teelen, Karina Hermsen, Rob Okell, Lucy Gosling, Roly Sauerwein, Robert Bousema, Teun Malar J Research BACKGROUND: Effective mass drug administration (MDA) with anti-malarial drugs can clear the human infectious reservoir for malaria and thereby interrupt malaria transmission. The likelihood of success of MDA depends on the intensity and seasonality of malaria transmission, the efficacy of the intervention in rapidly clearing all malaria parasite stages and the degree to which symptomatic and asymptomatic parasite carriers participate in the intervention. The impact of MDA with the gametocytocidal drug combination sulphadoxine-pyrimethamine (SP) plus artesunate (AS) plus primaquine (PQ, single dose 0.75 mg/kg) on malaria transmission was determined in an area of very low and seasonal malaria transmission in northern Tanzania. METHODS: In a cluster-randomized trial in four villages in Lower Moshi, Tanzania, eight clusters (1,110 individuals; cluster size 47- 209) were randomized to observed treatment with SP+AS+PQ and eight clusters (2,347 individuals, cluster size 55- 737) to treatment with placebo over three days. Intervention and control clusters were 1km apart; households that were located between clusters were treated as buffer zones where all individuals received SP+AS+PQ but were not selected for the evaluation. Passive case detection was done for the entire cohort and active case detection in 149 children aged 1-10 year from the intervention arm and 143 from the control arm. Four cross-sectional surveys assessed parasite carriage by microscopy and molecular methods during a five-month follow-up period. RESULTS: The coverage rate in the intervention arm was 93.0% (1,117/1,201). Parasite prevalence by molecular detection methods was 2.2-2.7% prior to the intervention and undetectable during follow-up in both the control and intervention clusters. None of the slides collected during cross-sectional surveys had microscopically detectable parasite densities. Three clinical malaria episodes occurred in the intervention (n = 1) and control clusters (n = 2). CONCLUSIONS: This study illustrates the possibility to achieve high coverage with a three-day intervention but also the difficulty in defining suitable outcome measures to evaluate interventions in areas of very low malaria transmission intensity. The decline in transmission intensity prior to the intervention made it impossible to assess the impact of MDA in the chosen study setting. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00509015 BioMed Central 2011-08-24 /pmc/articles/PMC3169516/ /pubmed/21864343 http://dx.doi.org/10.1186/1475-2875-10-247 Text en Copyright ©2011 Shekalaghe et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Shekalaghe, Seif A
Drakeley, Chris
van den Bosch, Sven
ter Braak, Roel
van den Bijllaardt, Wouter
Mwanziva, Charles
Semvua, Salimu
Masokoto, Alutu
Mosha, Frank
Teelen, Karina
Hermsen, Rob
Okell, Lucy
Gosling, Roly
Sauerwein, Robert
Bousema, Teun
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania
title A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania
title_full A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania
title_fullStr A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania
title_full_unstemmed A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania
title_short A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania
title_sort cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in tanzania
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169516/
https://www.ncbi.nlm.nih.gov/pubmed/21864343
http://dx.doi.org/10.1186/1475-2875-10-247
work_keys_str_mv AT shekalagheseifa aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT drakeleychris aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT vandenboschsven aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT terbraakroel aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT vandenbijllaardtwouter aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT mwanzivacharles aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT semvuasalimu aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT masokotoalutu aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT moshafrank aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT teelenkarina aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT hermsenrob aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT okelllucy aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT goslingroly aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT sauerweinrobert aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT bousemateun aclusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT shekalagheseifa clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT drakeleychris clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT vandenboschsven clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT terbraakroel clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT vandenbijllaardtwouter clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT mwanzivacharles clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT semvuasalimu clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT masokotoalutu clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT moshafrank clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT teelenkarina clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT hermsenrob clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT okelllucy clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT goslingroly clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT sauerweinrobert clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania
AT bousemateun clusterrandomizedtrialofmassdrugadministrationwithagametocytocidaldrugcombinationtointerruptmalariatransmissioninalowendemicareaintanzania